Intravitreal Anti-vascular Endothelial Growth Factor versus Observation in Acute Central Serous Chorioretinopathy: One-year Results.
10.3341/kjo.2014.28.4.306
- Author:
Sang Uk PARK
1
;
Seung Jun LEE
;
Moosang KIM
Author Information
1. Department of Ophthalmology, Kangwon National University School of Medicine, Chuncheon, Korea. moosangkim@kangwon.ac.kr
- Publication Type:Comparative Study ; Original Article
- Keywords:
Anti-vascular endothelial growth factor;
Central serous chorioretinopathy;
One year
- MeSH:
Acute Disease;
Adult;
Angiogenesis Inhibitors/*therapeutic use;
Bevacizumab/therapeutic use;
Central Serous Chorioretinopathy/*drug therapy/physiopathology;
Female;
Humans;
Intravitreal Injections;
Male;
Middle Aged;
Observation;
Ranibizumab/therapeutic use;
Retinal Photoreceptor Cell Inner Segment/pathology;
Retinal Photoreceptor Cell Outer Segment/pathology;
Retrospective Studies;
Subretinal Fluid/drug effects;
Tomography, Optical Coherence;
Vascular Endothelial Growth Factor A/antagonists & inhibitors;
Visual Acuity
- From:Korean Journal of Ophthalmology
2014;28(4):306-313
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: To evaluate the efficacy of anti-vascular endothelial growth factor (VEGF) compared with observation for treating acute central serous chorioretinopathy (CSC). METHODS: A retrospective study of 36 patients with acute CSC, including 21 patients treated with anti-VEGF (anti-VEGF group) and 15 patients with observation (observation group). Patients in the anti-VEGF group received a single dose of bevacizumab or ranibizumab at baseline. Best-corrected visual acuity (BCVA), central foveal thickness (CFT) and resolution of subretinal fluid (SRF) on optical coherence tomography (OCT) were assessed. The integrity of the foveal inner segment/outer segment (IS/OS) line at 12 months was also analyzed. RESULTS: Resolution of SRF was achieved in 20 of 21 eyes in the anti-VEGF group and in 12 of 15 eyes in the observation group (p = 0.151). Mean BCVA and CFT were not different between the two groups at 12 months (p > 0.05). The amount of change in BCVA, however, differed significantly between the groups (p = 0.044). Final OCT more frequently detected the foveal IS/OS line in the anti-VEGF group than in the observation group (p = 0.012). CONCLUSIONS: In terms of BCVA, anti-VEGF and observation only had similar therapeutic effects in acute CSC patients. In some patients, however, the rapid resolution of SRF by anti-VEGF might reduce the risk of photoreceptor degeneration and improve long-term visual acuity.
